As a symptom of an underlying condition, cough is one of the most comm
on reasons patients see physicians. To the majority, a cough means tha
t 'something is wrong' and it causes exhaustion and/or self-consciousn
ess. Patients find these reasons as well as effects on lifestyle, fear
of cancer and/or AIDS or tuberculosis to be the most troublesome conc
erns for which they seek medical attention. The treatment of cough can
be divided into two main categories: (a) therapy that controls, preve
nts or eliminates cough (i.e. antitussive); and (b) therapy that makes
cough more effective (i.e. protussive). Antitussive therapy can be ei
ther specific or nonspecific. Definitive or specific antitussive thera
py depends on determining the aetiology or operant pathophysiological
mechanism, and then initiating specific treatment. Since the cause of
chronic cough can almost always be determined, it is possible to presc
ribe specific therapy that can be almost uniformly successful. Nonspec
ific antitussive therapy is directed at the symptom; it is indicated w
hen definitive therapy cannot be given. Practically speaking, the effi
cacy of nonspecific therapy must be evaluated in double-blind, placebo
-controlled, randomised studies of pathological cough in humans. Such
studies have demonstrated the efficacy of dextromethorphan, codeine an
d ipratropium bromide aerosol in patients with chronic bronchitis. Whi
le the preferred treatment for patients with cough due to angiotensin
converting enzyme (ACE) inhibitor therapy is withdrawal of the offendi
ng drugs, it may be possible to ameliorate the cough by adding nifedip
ine, sulindac or indomethacin to the treatment regimen. The efficacy o
f protussive therapy has not been welt documented. Although hypertonic
saline aerosol and erdosteine in patients with bronchitis, and amilor
ide aerosol in patients with cystic fibrosis have been shown to improv
e mucus clearance, their clinical utility has not been adequately stud
ied.